

AD_____

Award Number: DAMD17-02-1-0629

TITLE: Structural Basis for the Pharmacological Rescue of Mutant
p53 with Small Molecule Compounds

PRINCIPAL INVESTIGATOR: William C. Ho

CONTRACTING ORGANIZATION: The Wistar Institute
Philadelphia, PA 19104

REPORT DATE: April 2005

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050819129

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE April 2005	3. REPORT TYPE AND DATES COVERED Annual Summary (1 Apr 2002 - 31 Mar 2005)	
4. TITLE AND SUBTITLE Structural Basis for the Pharmacological Rescue of Mutant p53 with Small Molecule Compounds			5. FUNDING NUMBERS DAMD17-02-1-0629	
6. AUTHOR(S) William C. Ho				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Wistar Institute Philadelphia, PA 19104 E-Mail: Who2@sas.upenn.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) The p53 protein is a tumor suppressor crucial to maintaining genomic integrity. In the event of DNA damage, p53 is responsible for transcribing genes leading to cell death. A class of mutations which occur in the core domain (102-292) leads to thermodynamic destabilization and inability to bind its cognate DNA sequence. Small molecules which bind to and stabilize mutant p53 core domain have potential to be therapeutically useful. Two potential "hot spots" on the surface of the mouse p53 core domain have been discovered which can be targeted by small molecule compounds. One hot spot was discovered by soaking the crystal lattice with various organic solvents and locating the solvents in the electron density. Another potential hot spot was located in the high resolution structure of the mouse core domain where a molecule of tris(hydroxymethyl)aminomethane (Tris) was observed to bind on the surface of the protein, making numerous hydrogen bonding contacts. Urea denaturation experiments show an increase in stability (~.37kcal/mol) in the presence of 1mM Tris when compared to protein in the absence of Tris. Although the gain in stability is relatively modest, the structural data acquired in this study can guide the way to designing compounds with increased activity.				
14. SUBJECT TERMS No subject terms provided.				15. NUMBER OF PAGES 13
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5-9
Key Research Accomplishments.....	10
Reportable Outcomes.....	11
Conclusions.....	12
References.....	13

Introduction

The p53 tumor suppressor protein is crucial to maintaining genomic integrity. In the event of DNA damage, p53 activates transcription of genes which lead to apoptosis or cell cycle arrest¹. As many as 50% of all human cancers are associated with mutations to p53². The p53 protein has four domains: an amino terminal transactivation domain (residues 1-44), a core DNA binding domain (102-292), a tetramerization domain (residues 320-356), and a carboxy-terminal regulatory domain (residues 320-356). An estimated 95% of all tumorigenic mutations to the p53 gene occur within the core domain³. Most of these mutations to the core domain occur as point mutations, which can be generally classified into two groups: 1) those which occur to amino acids making direct contact with DNA, thereby decreasing binding affinity, and 2) those which cause the core domain to be unstable, causing unfolding or misfolding, and therefore inability to bind DNA. To address mutations which cause the core domain to be unstable, attempts have been made to introduce small molecules which have the capability to bind to and stabilize the core domain, rescuing function. Among these attempts are those made by Freidler and co-workers⁴, who have designed a peptide with micromolar affinity and the ability to rescue human p53 core domain function. Knowledge of areas on the p53 core domain surface which can potentially be targeted by designed small molecules can be helpful.

Body

During the period of April 1, 2002 to April 30, 2005 for which my work was funded a number of goals were accomplished.

1.) *Synthesize a library of structurally diverse molecules that have been shown to pharmacologically rescue p53.* Based on the published work of Foster et al.⁵, molecules which were reported to interact with the p53 core domain were synthesized with the purpose of assaying binding and

determining the mode of binding via x-ray crystallography. In total four molecules were synthesized (Figure

1). All products were characterized via mass spectrometry and NMR spectroscopy.




Figure 1: (1.) N⁹-Acridin-9-yl-N,N-dimethyl-propane-1,3-diamine, (2.) N⁹-Acridin-9-yl-N,N-diethyl-propane-1,3-diamine), (3.) Acridin-9-yl[3-(4-methyl-piperazin-1-yl)propyl]-amine, (4.) Acridin-9-yl-(3-morpholin-4-yl-propyl)-amine

2.) *Crystallize the core domain of p53 in complex with a molecule shown to pharmacologically rescue p53.* Using the molecules synthesized above, crystallization trials with the mouse p53 core domain were initiated. However, no co-crystals were ever grown. Further studies with the compounds revealed that they did not interact with the mouse p53 core domain at all. Our findings were independently confirmed by the findings of Fersht⁶ et al. who also showed that the compounds published by Foster⁵ et al. did not interact directly with the human p53 core domain.

3.) *Structurally characterize the binding of peptides that have been shown to interact with and stabilize the p53 core domain using x-ray crystallography.* We became

interested in a paper published by the Fersht⁴ group detailing a number of peptides that were demonstrated to bind to and stabilize the p53 core domain. We then entered into a collaboration with the Fersht lab to solve the crystal structure of the peptides in complex with the mouse p53 core domain. With such a complex, we would then be able to use structure based drug design techniques to improve the desired properties of the peptides. Co-crystallization was attempted using both the mouse p53 core domain (92-292) and the human p53 core domain (94-32). No co-crystals were ever grown, although large well diffracting and well behaved crystals (1.55Å diffraction limit) of the mouse p53 core domain were obtained. At this point it was decided to use this crystal form as a tool to probe for “hot spots” which can potentially bind small molecules. Interestingly, other groups have also tried to grow co-crystals but were similarly unsuccessful.

4.) *Soak high resolution crystals of the mouse p53 core domain with organic solvents in order to locate possible binding sites for small molecules.* Crystals of the mouse p53




Figure 2: Fo-Fc omit map calculated at 2.56 using the final structure with isopropanol omitted.

core domain were soaked with a number of organic solvents 1,6 hexanediol, acetonitrile, isopropanol, acetone, and phenol in an attempt to locate “hot spots” that would be amenable to binding small molecules^{7; 8}. Typically, the crystals were soaked in ~35% organic solvent and the frozen. Data were collected at our home source and

then solvent molecules were located by viewing $f_o - f_c$, $f_o - f_o$ and $2f_o - f_c$ electron density maps. Of the solvents tested, only one molecule of isopropanol could be confidently located and assigned (figure 2). The hydroxyl functional group of isopropanol was observed to be bridging two α -sheets, while its methylene groups point to a hydrophobic region.

5.) Characterization of the Tris binding site on the surface of the mouse p53 core domain. During refinement of the high resolution structure (1.55Å) of the mouse p53 core domain, continuous electron density was observed which could not be accounted for by the protein itself, or water. A molecule of tris(hydroxymethyl)aminomethane (Tris), which was present in the mother liquor during crystallization was built into the electron density and refined for several cycles, resulting in an improvement of the model statistics. Tris fits very well into the electron density and is observed to make numerous hydrogen bonding contacts to neighboring residues; Y126 and Q128 interact with hydroxyl groups while D268 makes contacts with the amino group of Tris (Figure 3). Additionally, the Tris molecule




Figure 3: $F_o - F_c$ omit density of Tris bound to the p53 core domain contoured at 2.0 σ . Hydrogen bonding interactions are depicted in orange. Two molecules of water are depicted in red.

makes a water-mediated hydrogen bonding interactions to the backbone carbonyl of S266 and to the side chain nitrogen of Q101. It is interesting to note that D268 and Y126 are on opposing strands of anti-parallel beta sheets, in effect bridging S1 and S10. Further examination of the site of the Tris binding site reveals that Tris makes no inter-subunit

contacts in the crystal lattice and is therefore not likely to be an artifact of crystallization. To prove this, crystallization using Hepes as a buffer rather than Tris resulted in formation of crystals that were isomorphous in every property except for the absence of electron density in the proposed Tris binding site.

Although Tris clearly interacts with the mouse p53 core domain in the crystal structure, we were unsure of what effects, if any it has on the overall stability of the mouse p53 core domain. In order to characterize these possible effects, urea denaturation experiments were carried out in the presence and the absence of 1mM Tris. The data shows that addition of Tris provided a small, but noticeable increase in stability to the mouse p53 core domain (Figure 4). Without Tris, the mouse p53 core domain was observed have a midpoint of denaturation(U_m) of $2.39 \pm .01M$




Figure 4: Urea denaturation curve of mouse p53 core domain in the absence of Tris (red circles), and in the presence of 1mM Tris (black squares). Fluorescence of a single buried tryptophan was measured at 356nm with excitation at 280nm. Measurements were done in duplicate for 0mM Tris and quadruplicate for 1mM Tris.

Urea. In the presence of 1mM Tris, the U_m was observed to be $2.61 \pm .12M$ Urea. The increased stability was calculated to be $\sim .37kcal/mol$. Differential Scanning Calorimetry(DSC) was also attempted, but artifacts due to the thermal instability of Tris could not be eliminated. Our search for molecules based on Tris which impart increased stability is ongoing, although at this point, no other molecules have been discovered.

Nevertheless, our experiments with Tris demonstrate the feasibility of the concept that small molecules which bind to the core domain can impart stability.

Key Research Accomplishments:

- Synthesized a library of small molecules which were reported to bind to and stabilize the p53 core domain.

Attempted to grow crystals of the small molecule-p53 core domain complex.

It was discovered that this class of molecules does not interact with the mouse p53 core domain.

- Attempted to grow co-crystals of p53/peptides which Fersht et al. reported to bind to and stabilize the p53 core domain. Although both the mouse and human construct were used in crystallization trials, no co-crystals containing the protein/peptide complex were ever grown.

- Well behaved crystals of the mouse p53 core domain which diffracted extremely well (1.55 Å) at a synchrotron light source were grown. Data was collected and the structure was solved and refined.

Soaked this crystal form with several organic solvents in order to locate “hot spots” which might be able to accept small molecules. One molecule of isopropanol was observed to bind in a potential “hot spot”.

- Refined a high resolution structure of the mouse p53 core domain and uncovered a binding site for tris(hydroxymethyl)aminomethane (Tris).
- Assayed the effects of Tris on mouse p53 core domain stability using urea denaturation experiments. Tris was found to stabilize mouse p53 core domain ~ 3.7 kcal/mol as compared to “native” protein.

Reportable outcomes

“High resolution crystal structure of the mouse p53 core domain: An analysis of protein flexibility and a framework for structure-based drug design” Ho, W.C., Zhao, K., Chai, X., and Marmorstein, R.M., *manuscript submitted*.

“Acridine derivatives activate p53 and induce tumor cell death through Bax” Wang, W., Ho, W.C., Dicker, D.T., MacKinnon, C., Winkler, J.D., Marmorstein, R., El-Deiry, W.S., *manuscript submitted*.

Conclusions

Several conclusions can be reached from this funded work. First, we have observed, along with others that the molecules reported by Foster et al. do not interact directly with the p53 core domain. It has been speculated that the effects of these molecules are due to their actions on other pathways. Second, we believe that we have located a “hot spot” on the surface of the mouse p53 core domain using isopropanol affinity as a probe. This region has shown affinity for functional groups contained in isopropanol—a hydroxyl group and two methylene groups. Third, our structure of the mouse p53 core domain is the highest resolution structure (1.55Å) of the p53 core domain reported to date. This work provides a more detailed picture of the p53 core domain structure. Last, we have successfully found a small molecule that binds to and stabilizes the core domain. The increase in stability contributed by Tris binding is small (~ 0.37 kcal/mol). However, we believe that the results of this study are valuable in that it demonstrates the feasibility of small molecules which can bind to a specific site on the core domain and stabilize it. Available structural data supports our biochemical data and elucidates the exact nature of the interaction and thus has the potential for rationally developing molecules with improved function.

References

1. Zhao, K., Chai, X., Johnston, K., Clements, A., Marmorstein, R. (2001). Crystal structure of the mouse p53 core DNA-binding domain at 2.7Å resolution. *The Journal of Biological Chemistry* 276, 12120-12127.
2. Cho, Y., Gorina, S., Jeffrey, P.D., Pavletich, N.P. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. *Science* 265, 346-354.
3. Bullock, A. N., and Fersht, A.R. (2001). Rescuing the function of mutant p53. *Nature Reviews Cancer* 1, 68-76.
4. Freidler, A., Hansson, L.O., Veprintsev, D.B., Freund, S.M.V., Rippin, T.M., Nikolova, P.V., Proctor, M.R., Rudinger, S., Fersht, A.R. (2002). A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants. *PNAS* 99, 937-942.
5. Foster, B. A., Coffey, H.A., Morin, M.J., Rastinejad, F. (1999). Pharmacological rescue of mutant p53 conformation and function. *Science* 286, 2507-2510.
6. Rippin, T. M., Bykov, V.J.N., Freund, S.M.V., Selivanova, G., Wiman, K.G., Fersht, A.R. (2002). Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. *Oncogene* 21, 2119-2129.
7. English, A. C., Groom, C.R., Hubbard, R.E. (2001). Experimental and computational mapping of the binding surface of a crystalline protein. *Protein Engineering* 14, 47-59.
8. English, A. C., Done, S.H., Caves, L.S.D., Groom, C.R., Hubbard, R.E. (1999). Locating interactions sites on proteins: The crystal structure of thermolysin soaked in 2% to 100% isopropanol. *Proteins: Structure, Function and Genetics*, 628-640.